VistaGen Therapeutics Inc
NASDAQ:VTGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
hGears AG
XETRA:HGEA
|
DE |
|
H
|
Hufvudstaden AB
STO:HUFV A
|
SE |
|
B
|
Beijing Bashi Media Co Ltd
SSE:600386
|
CN |
VistaGen Therapeutics Inc
Accrued Liabilities
VistaGen Therapeutics Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
VistaGen Therapeutics Inc
NASDAQ:VTGN
|
Accrued Liabilities
$9.4m
|
CAGR 3-Years
73%
|
CAGR 5-Years
60%
|
CAGR 10-Years
23%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accrued Liabilities
$8.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accrued Liabilities
$3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accrued Liabilities
$2.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
19%
|
|
VistaGen Therapeutics Inc
Glance View
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system (CNS) disorders. The company is headquartered in South San Francisco, California and currently employs 31 full-time employees. The company went IPO on 2010-10-18. The firm is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The firm's pipeline includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that is preparing for Phase III clinical trial for social anxiety disorder (SAD), PH10, a neuroactive nasal spray that is planning for Phase 2b development as a stand-alone treatment for depressive disorder (MDD), and AV-101 which the Company is developing for the treatment of depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. In addition, the Company has developed a human pluripotent stem cell (hPSC) technology platform, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs).
See Also
What is VistaGen Therapeutics Inc's Accrued Liabilities?
Accrued Liabilities
9.4m
USD
Based on the financial report for Mar 31, 2025, VistaGen Therapeutics Inc's Accrued Liabilities amounts to 9.4m USD.
What is VistaGen Therapeutics Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
23%
Over the last year, the Accrued Liabilities growth was 236%. The average annual Accrued Liabilities growth rates for VistaGen Therapeutics Inc have been 73% over the past three years , 60% over the past five years , and 23% over the past ten years .
